The trusted source for
healthcare information and
Purchase access to this article; published in Clinical Cardiology Alert.
Despite the routine nature of discontinuing atrial fibrillation (AF) patients’ long-term oral anticoagulation (OAC) for procedures and “bridging” them with another agent, there is remarkably little data on the safety and benefit of this practice. Guidelines detailing when and how to initiate bridging therapy have been published, but data supporting why we should bridge at all are limited.1 To help fill this void, Steinberg and colleagues used a national, community-based registry of outpatients with AF (ORBIT-AF) to examine current practices around periprocedural OAC management and associated outcomes. Outcomes evaluated included rates of major bleeding, as well as myocardial infarction, stroke or systemic embolism, cause-specific hospitalization, and death within 30 days.
Each issue of Clinical Cardiology Alert contains 4-6 abstracts of developments in cardiology combined with expert physician commentary.
This peer-reviewed newsletter is designed to save you time - our physician editors do the reading and research for you! Topics covered include atrial fibrillation, myocardial infarction, ICD safety, preventive cardiology, and pharmacological approaches. In addition, you will have access to two online monthly supplements – Clinical Briefs in Primary Care and Pharmacology Watch.